Clinical Trial: Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational

Official Title: Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

Brief Summary: This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations

Detailed Summary:

This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision.

The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool.

The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.


Sponsor: Dana-Farber Cancer Institute

Current Primary Outcome: We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool [ Time Frame: Up to 5 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Evaluate Patient Experience With Genetic Testing [ Time Frame: up to 5 years ]
  • Summarize patient satisfaction with Genetic counseling [ Time Frame: up to 5 years ]
  • Number of patients who disclose genetic testing results to relatives [ Time Frame: up to 5 years ]


Original Secondary Outcome: Same as current

Information By: Dana-Farber Cancer Institute

Dates:
Date Received: February 15, 2017
Date Started: February 2017
Date Completion: February 2022
Last Updated: February 17, 2017
Last Verified: February 2017